Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial

BACKGROUND: Sodium-glucose co-transporter-2 inhibitors (SGLT2i) reduce glucose levels, body weight, and blood pressure, possibly resulting in cardiovascular protection. In phase III trials, SGLT2i were shown to increase HDL cholesterol. We aimed to evaluate whether the SGLT2i dapagliflozin affects H...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Cardiovasc Diabetol
Main Authors: Fadini, Gian Paolo, Bonora, Benedetta Maria, Zatti, Giancarlo, Vitturi, Nicola, Iori, Elisabetta, Marescotti, Maria Cristina, Albiero, Mattia, Avogaro, Angelo
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2017
Fag:
Original Investigation
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5379610/
https://ncbi.nlm.nih.gov/pubmed/28376855
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-017-0529-3
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker